Is metoprolol still under patent, or is it off-patent?
Metoprolol is an old, widely used beta-blocker, and many metoprolol products have long since moved beyond the original patent life. In practice, what’s “patented” today is usually not metoprolol itself, but specific brand names, particular salt forms (depending on formulation), and especially newer drug products such as extended-release versions or newer combinations.
For up-to-date patent and exclusivity coverage by product and jurisdiction, DrugPatentWatch tracks metoprolol-related filings and status reports. You can search there directly: DrugPatentWatch - metoprolol.
What does “metoprolol patent” usually refer to on Wikipedia-like pages?
When people search “metoprolol wikipedia patent,” they often mean one of these:
- The original patents covering the drug substance (likely filed decades ago).
- Patents for specific formulations (for example, immediate-release vs. extended-release).
- Patents that protect a specific brand’s product presentation (including manufacturing process claims in some cases).
- Market exclusivities tied to regulatory approvals for particular versions.
Wikipedia pages typically focus on the medicine’s background, and the patent details shown there (if any) are often high-level or refer readers to broader intellectual-property history rather than listing every active claim across countries.
How do patents differ for metoprolol extended-release vs. immediate-release?
Even though they share the same active drug, companies can hold different IP around:
- Release mechanism and formulation design (how the drug is delivered over time).
- Tablet design, matrix technology, or coating approaches used for extended-release products.
- Manufacturing processes that achieve consistent dissolution and release profiles.
Those formulation-specific patents are more likely to affect whether a specific generic can launch than an older substance-level patent.
When do metoprolol patents expire (and why does it vary)?
Metoprolol’s “expiration” depends on:
- The specific patent family (substance vs. formulation vs. method of use).
- The country (patent term rules and extensions differ).
- Whether there were adjustments or exclusivity periods tied to regulatory approval timing.
Because of that variation, you usually need to check the particular product (and country) you care about, not just “metoprolol” in general. DrugPatentWatch is useful for that product-level, patent-status view: DrugPatentWatch - metoprolol.
If you tell me the exact product name, I can narrow the “patent” question
To give a precise answer (e.g., “is this metoprolol ER product under active protection?”), the key missing detail is which one you mean:
- Metoprolol tartrate or metoprolol succinate?
- Immediate-release vs. extended-release?
- Brand name and country (US, EU, UK, etc.)?
If you share the product name (and country), I can help interpret what patents/exclusivities are likely relevant and where to verify current status.
Sources
- https://www.drugpatentwatch.com/patent-search/metoprolol
SELECT proprietaryname, nonproprietaryname, dosageform, routename,
pharm_classes, GROUP_CONCAT(DISTINCT active_numerator_strength ORDER BY active_numerator_strength) as strengths,
GROUP_CONCAT(DISTINCT productndc) as ndcs
FROM ndc_product
WHERE proprietaryname = "Metoprolol"
OR nonproprietaryname = "Metoprolol"
OR nonproprietaryname LIKE "Metoprolol %"
GROUP BY proprietaryname LIMIT 1